Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Labcorp Holdings ( (LH) ) has provided an update.
On June 27, 2025, Labcorp Holdings Inc. entered into a Fourth Amended and Restated Credit Agreement with Bank of America and other lenders, establishing a $1 billion senior unsecured revolving credit facility set to mature in 2030. This agreement replaces the previous credit facility due in 2026 and includes options to increase the credit amount, reflecting Labcorp’s strategic financial positioning and potential for expansion.
The most recent analyst rating on (LH) stock is a Buy with a $274.00 price target. To see the full list of analyst forecasts on Labcorp Holdings stock, see the LH Stock Forecast page.
Spark’s Take on LH Stock
According to Spark, TipRanks’ AI Analyst, LH is a Outperform.
Labcorp Holdings demonstrates a solid financial foundation and positive earnings outlook, supported by strategic initiatives and product innovation. While technical indicators and valuation suggest moderate risk, strong earnings growth and corporate governance measures enhance its overall attractiveness.
To see Spark’s full report on LH stock, click here.
More about Labcorp Holdings
Labcorp Holdings Inc. operates in the healthcare industry, primarily providing laboratory testing services and clinical trial management. The company focuses on offering comprehensive diagnostic solutions and advancing medical research, serving a wide range of healthcare providers and pharmaceutical companies.
Average Trading Volume: 810,061
Technical Sentiment Signal: Buy
Current Market Cap: $21.65B
Learn more about LH stock on TipRanks’ Stock Analysis page.